Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-MPS plus hydroxychloroquine vs hydroxychloroquine in high-risk IgA nephropathy
ChiCTR2400093530Phase 4Not yet recruiting
- Sponsor
- Shanxi Medical University Second Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mycophenolate sodium in IgA nephropathy (IgAN) (2 arms), sponsored by Shanxi Medical University Second Hospital. Primary endpoints: Change in 24-hour urine protein at 6 months vs baseline and Difference in rate of eGFR decline at 12 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
mycophenolate sodium
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2400093530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093530.